All lobbying filings

Ferox Strategies

Ferox Strategies filed a Q3 report for Fresenius Kabi USA LLC on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for Fresenius Kabi USA LLC · Generic and biosimilar pharmaceutical manufacturer

As filed: FEROX STRATEGIES for FRESENIUS KABI USA LLC.

All filings by Ferox Strategies · Everything Fresenius Kabi USA LLC has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Illinois

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

General healthcare issues related to biosimilar industries.

Pharmacy

General patent issues related to biosimilar industries.

Trade (domestic/foreign)

General issues related to trade.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.